- Home
- PSFE vs KALV Comparison
PSFE vs KALV Comparison
Compare PSFE & KALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSFE
- KALV
- Stock Information
- Founded
- PSFE 1996
- KALV N/A
- Country
- PSFE United Kingdom
- KALV United States
- Employees
- PSFE N/A
- KALV N/A
- Industry
- PSFE Business Services
- KALV Biotechnology: Pharmaceutical Preparations
- Sector
- PSFE Consumer Discretionary
- KALV Health Care
- Exchange
- PSFE Nasdaq
- KALV Nasdaq
- Market Cap
- PSFE 770.1M
- KALV 637.9M
- IPO Year
- PSFE N/A
- KALV N/A
- Fundamental
- Price
- PSFE $14.16
- KALV $13.41
- Analyst Decision
- PSFE Sell
- KALV Strong Buy
- Analyst Count
- PSFE 4
- KALV 9
- Target Price
- PSFE $17.38
- KALV $26.29
- AVG Volume (30 Days)
- PSFE 400.9K
- KALV 775.3K
- Earning Date
- PSFE 08-12-2025
- KALV 09-04-2025
- Dividend Yield
- PSFE N/A
- KALV N/A
- EPS Growth
- PSFE N/A
- KALV N/A
- EPS
- PSFE N/A
- KALV N/A
- Revenue
- PSFE $1,676,391,000.00
- KALV N/A
- Revenue This Year
- PSFE $3.06
- KALV N/A
- Revenue Next Year
- PSFE $6.77
- KALV $221.95
- P/E Ratio
- PSFE N/A
- KALV N/A
- Revenue Growth
- PSFE 0.47
- KALV N/A
- 52 Week Low
- PSFE $10.63
- KALV $7.30
- 52 Week High
- PSFE $26.25
- KALV $16.32
- Technical
- Relative Strength Index (RSI)
- PSFE 59.37
- KALV 51.45
- Support Level
- PSFE $13.02
- KALV $12.30
- Resistance Level
- PSFE $13.98
- KALV $13.52
- Average True Range (ATR)
- PSFE 0.78
- KALV 0.56
- MACD
- PSFE 0.15
- KALV 0.04
- Stochastic Oscillator
- PSFE 90.55
- KALV 91.11
About PSFE Paysafe Limited
Paysafe Ltd is an integrated payments platform. Its core purpose is to enable businesses and consumers to connect and transact seamlessly through capabilities in payment processing, digital wallet, and online cash solutions. The company provides payment solutions through three primary lines of business: Integrated Processing, Digital Wallet and eCash Solutions. It derives a majority of revenue from the USA followed by Germany, the UK, and all other countries.
About KALV KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.